IceCure Medical vs Pulse Biosciences
ICCM and PLSE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ICCM and PLSE compare
Pulse Biosciences grew revenue faster over the last twelve months (1637% versus 2.7% for IceCure Medical).
IceCure Medical keeps more of each dollar of sales as profit, with a net margin of −446% compared with −5604% at Pulse Biosciences.
Pulse Biosciences scores higher on the StockData Score (8 against 2 for IceCure Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ICCM | PLSE |
|---|---|---|
| Size and price | ||
| Market cap | – | $3.6B |
| Share price | $0.730 | $50.44 |
| Change, 1 year | −96.6% | 236% |
| Change, 5 years | −99.6% | 137% |
| Beta (5Y) | 0.69 | 1.24 |
| Employees | 67 | 116 |
| StockData Score | ||
| Total score | 2 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 0 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2408× |
| P/B | – | 19.6× |
| FCF yield | – | −1.8% |
| Growth | ||
| Revenue growth (TTM) | 2.7% | 1637% (better) |
| Revenue growth, 5Y average | −2.7% | – |
| EPS growth (TTM) | −20.0% | – |
| EPS growth, 5Y average | 1.8% | – |
| Profitability | ||
| Gross margin | 36.3% (better) | 26.8% |
| Operating margin | −447% (better) | −5821% |
| Net margin | −446% (better) | −5604% |
| FCF margin | −432% (better) | −4264% |
| Return on equity | −204% | −60.6% (better) |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Current ratio | 2.87 | 14.35 (better) |
| Altman Z-score | – | 115.81 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 3.8% | 15.0% |
| Held by insiders | – | 71.2% |
| Insider net buying, 12 months | – | $23.9M |
| Short interest, % of float | – | 14.1% |
Go deeper
- ICCM stock overview
- ICCM income statement
- ICCM valuation and score
- PLSE stock overview
- PLSE income statement
- PLSE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.